CD68 and neoplasm: Collectively, these results indicated that integrating tumor-specific biomarkers (HBx and CD68) with well-established clinical indicators could serve as a promising and reliable prognostic model with best predictive accuracy than the currently used single biomarker or clinical indicator for survival estimation.